Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

BACKGROUND: An unmet medical need exists for patients with metastatic renal cell carcinoma (RCC) who have progressed on a vascular endothelial growth factor (VEGF)–targeted therapy plus a mammalian target of rapamycin (mTOR) inhibitor. Fibroblast growth factor (FGF) pathway activation has been propo...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Oncol
Hoofdauteurs: Motzer, Robert J, Porta, Camillo, Vogelzang, Nicholas J, Sternberg, Cora N, Szczylik, Cezary, Zolnierek, Jakub, Kollmannsberger, Christian, Rha, Sun Young, Bjarnason, Georg A, Melichar, Bohuslav, De Giorgi, Ugo, Gruenwald, Viktor, Davis, Ian D, Lee, Jae-Lyun, Esteban, Emilio, Urbanowitz, Gladys, Cai, Can, Squires, Matthew, Marker, Mahtab, Shi, Michael, Escudier, Bernard
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5719485/
https://ncbi.nlm.nih.gov/pubmed/24556040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70030-0
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items